Treatment of Microcirculatory Disorders in Acute Liver Failure by an Endothelin- A Receptor Antagonist.

This article focuses on a study related to the treatment of microcirculatory disorders in acute liver failure by an endothelin- a receptor antagonist. Hepatocellular damage in acute liver failure (ALF) results both as a direct consequence of the initiating agent and indirect from the release of proinflammatory and cytotoxic mediators from activated, non-parenchymal sinusoidal-lining cells. Microcirculatory disorders are closely correlated to dysfunction of the liver during ALF. The treatment with selective antagonists of the endothelin-A-Receptor is a promising therapeutic approach of ALF by reducing microcirculatory lesions and their consequences affecting sinusoidal endothelium and hepatocytes.